Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.56 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29292083 | 0.86 | HDAC8 (0.51) | PLK1SLC7A5HDAC8HDAC6MRGPRX4 | |
| SCHEMBL13844842 | 0.86 | PLK1 (0.64) | PLK1SLC7A5HDAC8HDAC6KAT6A | |
| SCHEMBL11216517 | 0.85 | SMYD3 (0.60) | SLC7A5KAT6ASMYD3LOXL2CYP4F2 | |
| SCHEMBL1569614 | 0.85 | SLC7A5 (0.60) | PLK1SLC7A5HDAC8HDAC6SMYD3 | |
| SCHEMBL12142424 | 0.85 | HDAC6 (0.59) | HDAC8HDAC6KAT6ASMYD3HDAC3 | |
| SCHEMBL1569612 | 0.85 | SLC7A5 (0.60) | PLK1SLC7A5HDAC8HDAC6MRGPRX4 | |
| SCHEMBL16015431 | 0.84 | MRGPRX4 (0.53) | SLC7A5KAT6ASMYD3MRGPRX4LOXL2 | |
| SCHEMBL6388386 | 0.84 | LOXL2 (0.65) | PLK1SLC7A5HDAC8HDAC6MRGPRX4 | |
| SCHEMBL16103849 | 0.84 | SLC7A5 (0.59) | PLK1SLC7A5HDAC8HDAC6MRGPRX4 | |
| SCHEMBL14541727 | 0.84 | SLC7A5 (0.59) | PLK1SLC7A5HDAC8HDAC6MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193361-A1 | METHODS AND COMPOSITIONS USEFUL FOR NUCLEIC ACID SEQUENCING | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-22 | — | — | US | disclosed |
| US-20230119408-A1 | NUCLEOTIDE ANALOGS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-04-20 | — | — | US | disclosed |
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-05 | — | — | US | disclosed |
| WO-2022128843-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022128848-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-23 | — | — | WO | disclosed |
| US-11174281-B1 | Modified nucleotides and uses thereof | Singular Genomics Systems, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021216998-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| WO-2021158463-A1 | DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021066608-A1 | COMPOUND FOR INDUCING EXPRESSION OF ANTI-AGING GENE KLOTHO AND USE THEREOF | 주식회사 클로소사이언스 | 2021-04-08 | — | — | WO | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100210638-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-19 | — | — | US | disclosed |
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
| WO-2005023812-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | PLK1 222/4885SLC7A5 4200/4885HDAC8 1079/4885 |
| US-20230119408-A1 | NUCLEOTIDE ANALOGS AND USES THEREOF | NUDT1, PNP, NT5C2 | PLK1 2303/4885SLC7A5 1384/4885HDAC8 2073/4885 |
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K5, MAPK1, MAPKAPK5 | PLK1 283/4885SLC7A5 715/4885HDAC8 353/4885 |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | PLK1 566/4885SLC7A5 1102/4885HDAC8 3010/4885 |
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | NUDT1, RNMT, ADAR | PLK1 2287/4885SLC7A5 2905/4885HDAC8 2065/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | PLK1 566/4885SLC7A5 1102/4885HDAC8 3010/4885 |
| US-20100210638-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | PLK1 3884/4885SLC7A5 329/4885HDAC8 3179/4885 |
| US-11174281-B1 | Modified nucleotides and uses thereof | NUDT1, RNMT, ADAR | PLK1 2287/4885SLC7A5 2905/4885HDAC8 2065/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PLK1 2579/4885SLC7A5 842/4885HDAC8 202/4885 |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | PLK1 2811/4885SLC7A5 1072/4885HDAC8 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.